PMID- 33315534
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Dec
TI  - The underlying molecular mechanism and identification of transcription factor 
      markers for laryngeal squamous cell carcinoma.
PG  - 208-224
LID - 10.1080/21655979.2020.1862527 [doi]
AB  - The screening and treatment of laryngeal squamous cell carcinoma (LSCC) still 
      perplexes clinicians, making it necessary to explore new markers. To this end, 
      this research examined the underlying molecular mechanism of LSCC based on 
      high-throughput datasets (n = 249) from multiple databases. It also identified 
      transcription factors (TFs) independently associated with LSCC prognosis. Through 
      Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses, differential 
      expression genes of LSCC were deemed relevant to the extracellular matrix and its 
      related structures or pathways, suggesting that the extracellular matrix plays an 
      important role in LSCC. At the same time, several hub genes that may also have 
      important roles in LSCC were identified via protein-protein interaction analysis, 
      including CDC45, TPX2, AURKA, KIF2C, NUF, MUC1, MUC7, MUC4, MUC15, and MUC21. 
      Eight unreported LSCC prognostic TFs - BCAT1, CHD4, FOXA2, GATA6, HNF1A, HOXB13, 
      MAFF, and TCF4 - were screened via Kaplan-Meier curves. Cox analysis determined 
      for the first time that HOXB13 expression and gender were independently 
      associated with LSCC prognosis. Compared to control tissues, elevated expression 
      of HOXB13 was found in LSCC tissues (standardized mean difference = 0.44, 95% 
      confidence interval [0.13-0.76]). HOXB13 expression also makes it feasible to 
      screen LSCC from non-LSCC (area under the curve = 0.77), and HOXB13 may play an 
      essential role in LSCC by regulating HOXB7. In conclusion, HOXB13 may be a novel 
      marker for LSCC clinical screening and treatment.
FAU - Mo, Bin-Yu
AU  - Mo BY
AD  - Department of Otolaryngology, Liuzhou People's Hospital of Guangxi , Liuzhou, 
      Guangxi Zhuang Autonomous Region, P.R. China.
FAU - Li, Guo-Sheng
AU  - Li GS
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University , Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
FAU - Huang, Su-Ning
AU  - Huang SN
AD  - Department of Radiotherapy, Guangxi Medical University Cancer Hospital , Nanning, 
      Guangxi Zhuang Autonomous Region, P.R. China.
FAU - He, Wei-Ying
AU  - He WY
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University , Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
FAU - Xie, Li-Yuan
AU  - Xie LY
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University , Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
FAU - Wei, Zhu-Xin
AU  - Wei ZX
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University , Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
FAU - Su, Ya-Si
AU  - Su YS
AD  - Department of Pathology, Liuzhou People's Hospital , Liuzhou, Guangxi Zhuang 
      Autonomous Region, P.R. China.
FAU - Liang, Yue
AU  - Liang Y
AD  - Department of Pathology, Liuzhou People's Hospital , Liuzhou, Guangxi Zhuang 
      Autonomous Region, P.R. China.
FAU - Yang, Li
AU  - Yang L
AD  - Department of Pathology, Liuzhou People's Hospital , Liuzhou, Guangxi Zhuang 
      Autonomous Region, P.R. China.
FAU - Ye, Cheng
AU  - Ye C
AD  - Department of Pathology, Liuzhou People's Hospital , Liuzhou, Guangxi Zhuang 
      Autonomous Region, P.R. China.
FAU - Dai, Wen-Bin
AU  - Dai WB
AD  - Department of Pathology, Liuzhou People's Hospital , Liuzhou, Guangxi Zhuang 
      Autonomous Region, P.R. China.
FAU - Ruan, Lin
AU  - Ruan L
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University , Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HOXB13 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - *Biomarkers, Tumor/genetics/metabolism
MH  - Databases, Genetic
MH  - Female
MH  - *Head and Neck Neoplasms/diagnosis/genetics/metabolism/mortality
MH  - Homeodomain Proteins/genetics/metabolism
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Protein Interaction Maps/genetics
MH  - *Squamous Cell Carcinoma of Head and Neck/diagnosis/genetics/metabolism/mortality
MH  - *Transcription Factors/genetics/metabolism
PMC - PMC8291796
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - RNA sequencing
OT  - homeobox B13
OT  - prognosis
OT  - transcription factor
COIS- The authors report no conflict of interest.
EDAT- 2020/12/15 06:00
MHDA- 2021/11/16 06:00
PMCR- 2021/01/04
CRDT- 2020/12/14 17:12
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2020/12/14 17:12 [entrez]
PHST- 2021/01/04 00:00 [pmc-release]
AID - 1862527 [pii]
AID - 10.1080/21655979.2020.1862527 [doi]
PST - ppublish
SO  - Bioengineered. 2021 Dec;12(1):208-224. doi: 10.1080/21655979.2020.1862527.